Demographic/medical variables versus fibrosis for patients with biopsies less than 10 years from diagnosis (n = 34 patients)
. | Fibrosis score . | . | |
|---|---|---|---|
| Variable . | 0-2 n = 16 (%) . | 3-6 n = 18 (%) . | |
| Sex | |||
| Male | 8 (47.1) | 9 (52.9) | |
| Female | 8 (47.1) | 9 (52.9) | |
| Race* | |||
| White | 11 (42.3) | 15 (57.7) | |
| Black | 5 (100.0) | 0 (0.0) | |
| Hispancic/other | 0 (0.0) | 3 (100.0) | |
| Age at diagnosis, y | |||
| 0-6 | 8 (47.1) | 9 (52.9) | |
| 7-20 | 8 (47.1) | 9 (52.9) | |
| Diagnosis | |||
| ALL/AML | 12 (42.9) | 16 (57.1) | |
| Other malignancies | 4 (66.7) | 2 (33.3) | |
| Genotype† | |||
| 1 | 9 (42.9) | 12 (57.1) | |
| Other | 5 (71.4) | 2 (28.6) | |
| No. of alkylating agents | |||
| 0 | 5 (50.0) | 5 (50.0) | |
| 1 | 8 (50.0) | 8 (50.0) | |
| 2 | 3 (37.5) | 5 (62.5) | |
| No. of antimetabolites* | |||
| 0 | 4 (80.0) | 1 (20.0) | |
| 1 | 3 (75.0) | 1 (25.0) | |
| 2 | 1 (16.7) | 5 (83.3) | |
| 3-4‡ | 8 (42.1) | 11 (57.9) | |
| No. of antibiotics | |||
| 0 | 4 (40.0) | 6 (60.0) | |
| 1 | 10 (52.6) | 9 (47.4) | |
| 2 | 2 (40.0) | 3 (60.0) | |
| Chemotherapy score§ | |||
| Mean ± SD | 6.7 ± 2.7 | 7.6 ± 2.5 | |
| Median (range) | 6.5 (3-11) | 7 (3-12) | |
. | Fibrosis score . | . | |
|---|---|---|---|
| Variable . | 0-2 n = 16 (%) . | 3-6 n = 18 (%) . | |
| Sex | |||
| Male | 8 (47.1) | 9 (52.9) | |
| Female | 8 (47.1) | 9 (52.9) | |
| Race* | |||
| White | 11 (42.3) | 15 (57.7) | |
| Black | 5 (100.0) | 0 (0.0) | |
| Hispancic/other | 0 (0.0) | 3 (100.0) | |
| Age at diagnosis, y | |||
| 0-6 | 8 (47.1) | 9 (52.9) | |
| 7-20 | 8 (47.1) | 9 (52.9) | |
| Diagnosis | |||
| ALL/AML | 12 (42.9) | 16 (57.1) | |
| Other malignancies | 4 (66.7) | 2 (33.3) | |
| Genotype† | |||
| 1 | 9 (42.9) | 12 (57.1) | |
| Other | 5 (71.4) | 2 (28.6) | |
| No. of alkylating agents | |||
| 0 | 5 (50.0) | 5 (50.0) | |
| 1 | 8 (50.0) | 8 (50.0) | |
| 2 | 3 (37.5) | 5 (62.5) | |
| No. of antimetabolites* | |||
| 0 | 4 (80.0) | 1 (20.0) | |
| 1 | 3 (75.0) | 1 (25.0) | |
| 2 | 1 (16.7) | 5 (83.3) | |
| 3-4‡ | 8 (42.1) | 11 (57.9) | |
| No. of antibiotics | |||
| 0 | 4 (40.0) | 6 (60.0) | |
| 1 | 10 (52.6) | 9 (47.4) | |
| 2 | 2 (40.0) | 3 (60.0) | |
| Chemotherapy score§ | |||
| Mean ± SD | 6.7 ± 2.7 | 7.6 ± 2.5 | |
| Median (range) | 6.5 (3-11) | 7 (3-12) | |
No significant differences were detected.
Significant association (P < .05) between variable and fibrosis score. Two categories are presented, but fibrosis score was analyzed as ordinal values ranging from 0 to 6 using exact tests, given the small sample sizes (linear-by-linear association tests for individual chemotherapy agents and Kruskal-Wallis categorical tests for sex through genotype)
Genotype only available on 14 subjects
One patient in the 3-6 fibrosis score group had 4 antimetabolites. The remaining patients had 3
For chemotherapy score, the nonparametric Kruskal-Wallis test and ordinary least squares regression were used